Ipca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 25377.19 Crore) operating in Pharmaceuticals sector.
By ETMarkets.com | Updated:
Getty Images
Promoters held 46.1 per cent stake in the company as of June 30, 2020, while FIIs held 12.4 per cent, DIIs 19 per cent and public and others 13.3 per cent.
Motilal Oswal has given buy rating to Ipca Laboratories with a target price of Rs 2420. The share price moved down by by 0.43 per cent from its previous close of Rs 2008.40. The stock’s last traded price is Rs 2008.40.
Ipca Laboratories Ltd., incorporated in the year 1949, is a Mid Cap company (having a market cap of Rs 25377.19 Crore) operating in Pharmaceuticals sector. Financials For the quarter ended 30-06-2020, the company reported a Consolidated sales of Rs 1534.40 Crore, up 42.90 % from last quarter Sales of Rs 1073.76 Crore and up 42.31 % from last year same quarter Sales of Rs 1078.19 Crore Company has reported net profit after tax of Rs 446.75 Crore in latest quarter. Investment Rationale The brokerage remains positive on IPCA on the back of: a) superior performance in the DF segment, b) the addition of new APIs as well as increased traction in existing API molecules, c) product launches under its own label in the UK, and d) increased backward integration to derive further benefit by improving manufacturing efficiency.
Promoter/FII Holdings Promoters held 46.1 per cent stake in the company as of June 30, 2020, while FIIs held 12.4 per cent, DIIs 19 per cent and public and others 13.3 per cent.
